Mizutani Taro, Tadauchi Akimitsu, Arinobe Manabu, Narita Yuji, Kato Ryuji, Niwa Yasumasa, Ohmiya Naoki, Itoh Akihiro, Hirooka Yoshiki, Honda Hiroyuki, Ueda Minoru, Goto Hidemi
Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1150-6.
BACKGROUND/AIMS: Recently, novel endoscopic surgery, including endoscopic submucosal dissection (ESD), was developed to resect a large superficial gastrointestinal cancer. However, circumferential endoscopic surgery in the esophagus can lead to esophageal stricture that affects the patient's quality of life. This major complication is caused by scar formation, and develops during the two weeks after endoscopic surgery. We hypothesized that local administration of a controlled release anti-scarring agent can prevent esophageal stricture after endoscopic surgery. The aims of this study were to develop an endoscopically injectable anti-scarring drug delivery system, and to verify the efficacy of our strategy to prevent esophageal stricture.
We focused on 5-Fluorouracil (5-FU) as an anti-scarring agent, which has already been shown to be effective not only for treatment of cancers, but also for treatment of hypertrophic skin scars. 5-FU was encapsulated by liposome, and then mixed with injectable 2% atelocollagen (5FLC: 5FU-liposome-collagen) to achieve sustained release. An in vitro 5-FU releasing test from 5FLC was performed using high-performance liquid chromatography (HPLC). Inhibition of cell proliferation was investigated using normal human dermal fibroblast cells (NHDF) with 5FLC. In addition, a canine esophageal mucosal resection was carried out, and 5FLC was endoscopically injected into the ulcer immediately after the operation, and compared with a similar specimen injected with saline as a control.
5-FU was gradually released from 5FLC for more than 2 weeks in vitro. The solution of 5-FU released from 5FLC inhibited NHDF proliferation more effectively than 5-FU alone. In the canine model, no findings of stricture were observed in the 5FLC-treated dog at 4 weeks after the operation and no vomiting occurred. In contrast, marked esophageal strictures were observed with repeated vomiting in the control group. Submucosal fibrosis was markedly reduced histologically in the 5FLC-treated dog compared with the control.
5FLC showed sustained release of 5-FU and decreased cell proliferation in vitro. The clinically relevant canine model demonstrated that local endoscopic injection of 5FLC can prevent post-operative esophageal stricture. These results suggest that our strategy may be useful for preventing post-operative esophageal stricture.
背景/目的:近年来,包括内镜黏膜下剥离术(ESD)在内的新型内镜手术被用于切除大型浅表性胃肠道癌。然而,食管的环形内镜手术可导致食管狭窄,影响患者生活质量。这种主要并发症是由瘢痕形成引起的,且在内镜手术后两周内发生。我们推测局部应用控释抗瘢痕形成剂可预防内镜手术后的食管狭窄。本研究的目的是开发一种可内镜注射的抗瘢痕形成药物递送系统,并验证我们预防食管狭窄策略的有效性。
我们将5-氟尿嘧啶(5-FU)作为抗瘢痕形成剂,它已被证明不仅对癌症治疗有效,而且对肥厚性皮肤瘢痕治疗也有效。5-FU被脂质体包裹,然后与可注射的2%去端肽胶原混合(5FLC:5-氟尿嘧啶-脂质体-胶原)以实现缓释。使用高效液相色谱法(HPLC)对5FLC进行体外5-FU释放试验。用5FLC对正常人皮肤成纤维细胞(NHDF)进行细胞增殖抑制研究。此外,进行犬食管黏膜切除术,术后立即在内镜下将5FLC注入溃疡,并与注入生理盐水作为对照的类似标本进行比较。
5-FU在体外从5FLC中逐渐释放超过2周。从5FLC释放的5-FU溶液比单独的5-FU更有效地抑制NHDF增殖。在犬模型中,术后4周,接受5FLC治疗的犬未观察到狭窄,也未发生呕吐。相比之下,对照组出现明显的食管狭窄并伴有反复呕吐。与对照组相比,5FLC治疗的犬组织学上黏膜下纤维化明显减轻。
5FLC在体外显示5-FU的持续释放并减少细胞增殖。临床相关的犬模型表明,内镜下局部注射5FLC可预防术后食管狭窄。这些结果表明我们的策略可能对预防术后食管狭窄有用。